Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma
June 08, 2020 09:00 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients
May 27, 2020 16:30 ET
|
Aerpio Pharmaceuticals, Inc.
SAN FRANCISCO and CINCINNATI, May 27, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an...
Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)
May 12, 2020 16:30 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, May 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update
May 07, 2020 08:00 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, May 07, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 16, 2020 08:00 ET
|
Aerpio Pharmaceuticals, Inc.
Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 2021 Conference Call and Webcast Today, March 16,...
Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020
March 12, 2020 17:00 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, March 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases...